ArticleThe Journal of pharmacology and experimental therapeutics2019
Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of
Open access · hybridAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Synthesis and evaluation of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydromorphinone derivatives: mixed partial agonists at mu opioid and nociception/orphanin FQ peptide receptors.RSC medicinal chemistry · 2026Article
- Eating a high fat/high carbohydrate diet enhances morphine tolerance, while eating a ketogenic diet mitigates morphine withdrawal in male rats.European journal of pharmacology · 2025Article
- Structural basis of μ-opioid receptor targeting by a nanobody antagonist.Nature communications · 2024Article
- The Effects of Eating a Traditional High Fat/High Carbohydrate or a Ketogenic Diet on Sensitivity of Female Rats to Morphine.The Journal of pharmacology and experimental therapeutics · 2024Article
- Antinociceptive effects of fentanyl and nonopioid drugs in methocinnamox-treated rats.Drug and alcohol dependence · 2024Article
- Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder.Journal of the experimental analysis of behavior · 2023Article
- Effects of Daily Methocinnamox Treatment on Fentanyl Self-Administration in Rhesus Monkeys.The Journal of pharmacology and experimental therapeutics · 2022Article
- The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review.Pharmacy (Basel, Switzerland) · 2022Review
- Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox.Pharmacology research & perspectives · 2021Article
- Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats.The Journal of pharmacology and experimental therapeutics · 2021Article
- Countermeasures for Preventing and Treating Opioid Overdose.Clinical pharmacology and therapeutics · 2021Review
- Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys.Psychopharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Lisa R GerakDepartments of Pharmacology (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.) and Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.).
Vanessa MinerviniDepartments of Pharmacology (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.) and Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.).
Elizabeth LathamDepartments of Pharmacology (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.) and Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.).
Saba GhodratiDepartments of Pharmacology (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.) and Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.).
Katherine V LillisDepartments of Pharmacology (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.) and Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.).
Jessica WoodenDepartments of Pharmacology (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.) and Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.).
Alex DisneyDepartments of Pharmacology (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.) and Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.).
Stephen M HusbandsDepartments of Pharmacology (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.) and Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.).
Charles P FranceDepartments of Pharmacology (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.) and Psychiatry (C.P.F.), and Addiction Research, Treatment & Training Center of Excellence (L.R.G., V.M., E.L., S.G., K.V.L., J.W., C.P.F.), University of Texas Health Science Center at San Antonio, San Antonio, Texas; and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom (A.D., S.M.H.) france@uthscsa.edu.
University of Bath · GBThe University of Texas Health Science Center at San Antonio · US
Funding
Training in Drug Abuse Research: Behavior and NeurobiologyT32DA031115 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHARLES P FRANCE · 2011 to 2026
$5.2MNarcotic Drug and Opioid Peptide Basic Research projectP01DA000254 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WOODS, JAMES H · 2003 to 2006
$5.0MDISCOVERY OF NEW TREATMENTS FOR INTRAVENOUS DRUG ABUSER01DA007315 · NIDA · UNIVERSITY OF BRISTOL · PI HUSBANDS, STEPHEN M, TRAYNOR, JOHN R. · 1991 to 2019
$4.8MA novel opioid receptor antagonist for treating abuse and overdoseR01DA048417 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FRANCE, CHARLES P · 2019 to 2023
$2.6MNIDA NIH HHS P01 DA000254NIDA NIH HHS R01 DA007315NIDA NIH HHS R01 DA048417NIDA NIH HHS T32 DA031115
Abstract
A novel
Indexed as
Analgesics, OpioidAnimalsCinnamatesDose-Response Relationship, DrugMaleMorphine DerivativesNarcotic AntagonistsPain MeasurementRandom AllocationRatsRats, Sprague-DawleyReceptors, Opioid, muSubstance Withdrawal SyndromeAnalgesics, OpioidCinnamatesmethocinnamoxMorphine DerivativesNarcotic AntagonistsReceptors, Opioid, mu
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.